Angiogenic switch as a molecular target of malignant tumors

Journal of Gastroenterology

Volumn 38, Issue SUPPL. 15, 2003, Pages 93-97

  Tanaka, Shinji ^a   Sugimachi, Keishi ^a   Yamashita, Yo Ichi ^a   Shirabe, Ken ^a   Shimada, Mitsuo ^a   Wands, Jack R ^b   Sugimachi, Keizo ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b BROWN UNIVERSITY   (United States)

^c KYUSHU CENTRAL HOSPITAL   (Japan)

Author keywords

Angiogenic switch; Angiopoietin; Hepatocellular carcinoma; Tie2; Tumor dormacy

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 2; CD31 ANTIGEN; LIGAND; SURVIVIN; TYROSINE KINASE RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CARCINOGENICITY; CONTROLLED STUDY; DNA MODIFICATION; DOMINANT GENE; DRUG TARGETING; ENDOTHELIUM CELL; EXPRESSION VECTOR; GENE CONSTRUCT; GENE IDENTIFICATION; GENE ISOLATION; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR BLEEDING; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INDUCING AGENTS; ANGIOPOIETIN-2; ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GENE TARGETING; HUMANS; LIVER NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0037258491     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
3. Tanaka S, Sugimachi K, Maehara S, Shirabe K, Shimada M, Wands JR, et al. Oncogenic signal transduction and therapeutic strategy for hepatocellular carcinoma. Surgery 2002;131:S142-7.
4. Sugimachi K, Tanaka S, Terashi T. Taguchi K, Shimada M, Sugimachi K. The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression. Surgery 2002;131:S135-41.
5. Sonoda T, Shirabe K, Takenaka K, Kanematsu T, Yasumori K, Sugimachi K. Angiographically undetected small hepatocellular carcinoma: clinicopathological characteristics, follow-up and treatment. Hepatology 1989;10:1003-7.
6. Kawahara N, Ono M, Taguchi K, Okamoto M, Shimada M, Takenaka K, et al. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 1998;28:1512-7.
7. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998;27:1554-62.
8. Shiraishi T, Mori M, Tanaka S, Akiyoshi T, Sugimachi K. Identification of cystatin B in human esophageal carcinoma using differential displays in which the gene expression is related to lymph node metastasis. Int J Cancer 1998;79:175-8.
9. Tanaka S, Akiyoshi T, Mori M, Wands JR, Sugimachi K. A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals. Proc Natl Acad Sci U S A 1998;95: 10164-9.
10. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
11. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-9.
12. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, Koh GY. Angiopoietin-2 at high concentrations can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 2000;19:4549-52.
13. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PD, Sato TN, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87: 1171-80.
14. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999;103:341-5.
15. Tanaka S, Sugimachi K, Yamashita Y, Ohga T, Shirabe K, Shimada M, et al. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 2002;35: 861-7.
16. Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H, et al. Identification of Tek/Tie2 binding partners. Binding to a multi-functional docking site mediates cell survival and migration. J Biol Chem 1999;274:30896-905.
17. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000;275: 9102-5.
18. Tanaka S, Mori M, Akiyoshi T, Tanaka Y, Mafune K, Wands JR, et al. Co-expression of Grb7 with EGFR or Her2/erbB2 in human advanced esophageal carcinoma. Cancer Res 1997;57:28-31.
19. Tanaka S, Mori M, Akiyoshi T, Tanaka Y, Mafune K, Wands JR, et al. A novel variant of human Grb7 is associated with invasive esophageal carcinoma. J Clin Invest 1998;102:821-7.
20. Tanaka S, Kawaguchi H, Saeki H, Sugimachi K, Ohno S, Wands JR, Sugimachi K. Grb7 signal transduction protein mediates metastatic progression of esophageal carcinoma. J Cell Physiol 2000;183:411-5.
21. Etoh T, Inoue H, Tanaka S, Bernard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 2001;61:2145-53.
22. Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, Shimada M, et al. A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene 2001;20(39):5525-32.
23. Tanaka S, Ito T, Wands JR. Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with Grb2 and Syp signaling molecules. J Biol Chem 1996;271:14610-6.
24. 1 induced apoptosis. Cancer Res 1996;56:3391-4.
25. Runting AS, Stacker SA, Wilks AF. Tie2, a putative protein tyrosine kinase from a new class of cell surface receptor. Growth Factors 1993;9:99-105.
26. Tanaka S, Wands JR. A carboxy-terminal truncated IRS-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. J Clin Invest 1996;98:2100-8.
27. Yamashita Y, Shimada M, Hasegawa K, Minagawa R, Rikimaru T, Hamatsu T, et al. Electroporation-mediated IL-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 2001;61:1005-12.
28. Ince N, Wands JR. The increasing incidence of hepatocellular carcinoma. N Engl J Med 1999;340:798-9.
29. Adachi E, Maehara S, Tsujita E, Taguchi K, Aishima S, Rikimaru T, et al. Clinicopathologic risk factors for recurrence after a curative hepatic resection for hepatocellular carcinoma. Surgery 2002;131:S148-52.